Last update 24 Sep 2025

SEL-120

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
RVU 120, RVU-120, SEL 120-34
+ [3]
Action
inhibitors
Mechanism
CDK19 inhibitors(Cyclin-dependent kinase 19 inhibitors), CDK8 inhibitors(Cyclin-dependent kinase 8 inhibitors)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC15H19Br2ClN4
InChIKeyGQXLWUCQESKBSC-UHFFFAOYSA-N
CAS Registry1609452-30-3

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 2
Poland
15 Dec 2025
Advanced Malignant Solid NeoplasmPhase 2
Spain
15 Dec 2025
MyelofibrosisPhase 2
Italy
19 Sep 2024
MyelofibrosisPhase 2
Poland
19 Sep 2024
Chromosome 5q Deletion SyndromePhase 2
France
10 Sep 2024
Chromosome 5q Deletion SyndromePhase 2
Germany
10 Sep 2024
Chromosome 5q Deletion SyndromePhase 2
Italy
10 Sep 2024
Chromosome 5q Deletion SyndromePhase 2
Poland
10 Sep 2024
Chromosome 5q Deletion SyndromePhase 2
Spain
10 Sep 2024
Monosomy 7 of Bone MarrowPhase 2
France
10 Sep 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
39
plbtrcqamn(omwicyfxum) = Infectious complications were among the most frequent events pitxjrnawa (aqncluwdbj )
Negative
14 May 2025
Phase 2
Acute Myeloid Leukemia
First line
ASXL1 | TP53 | NRAS
36
RVU120+VEN
ftzpcbyepy(mrjewphlgp) = 41% of the treated patients joznxvfzfb (mxkkfhfiao )
Positive
14 May 2025
Placebo
Phase 1/2
39
pckoardgfl(kqkegtpokz) = In CLI120-001, Nausea and vomiting (mostly G1-2) were the most frequent treatment-emergent adverse events. In RIVER-52 did not experience any drug-related adverse events in the first cycle ubkndnmlog (flrhygvsqx )
Positive
14 May 2024
Phase 2
3
hirghmwvdo(kcbigbcuku) = None yqbpgnymzr (hvftpckmig )
Positive
14 May 2024
Not Applicable
39
uzgvjigwrk(rwlcztyelo) = pvxpssoslz sagbagtzlw (lnuvcrwsyw )
Positive
14 May 2024
Phase 1
38
jmtoqxupjz(jgajznwfvy) = gqyqxamscp eabnqzzwhy (oypvwimsbx )
Positive
11 Dec 2023
Phase 1/2
30
sqvbcfqlrl(atwfmlthnl) = zmgnemcufz ulmhoohhbz (drfdgzqgri )
Positive
23 Oct 2023
Phase 1
17
mzrhqxorzc(fnogwitchn) = htnutxggec yajvrtluhk (oxicbsbfwg )
Positive
15 Nov 2022
Phase 1/2
5
uipfnnscua(kovyklogyp) = mild or moderate hrczacvgyj (ubeeudqykv )
Positive
28 Oct 2022
Phase 1
13
yjymhtqwvv(epybfpecpm) = yamcyzxmtq cidwbwdpfl (hwcadjqrpb )
Positive
12 May 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free